Today the NSW Government announced $143.3 million funding over four years for the Sydney Biomedical Accelerator.
Today’s announcement is a continuation of the NSW Government’s commitment to transforming the economy with new high value jobs in science, technology and medical research. The SBA will be a keystone of the recently established Tech Central precinct that will deliver a vibrant innovation and technology community in the heart of Sydney.
The SBA will be a state-of-the-art biomedical research complex complementing the University of Sydney and the Royal Prince Alfred Hospital campuses, offering a unique global concentration of biomedical research talent.
“Our patients are at the centre of everything we do and we are always looking for ways to improve their lives so this announcement is very exciting,” Sydney Local Health District Chief Executive Dr Teresa Anderson said. “Investing in these state-of-the-art facilities will dramatically shorten the time between scientific discovery and health outcomes for patients and their families, getting people the answers they need faster.
“The SBA will also help us solve critical health challenges and revolutionise health care solutions for generations to come. It will offer a unique global concentration of biomedical research talent and research facilities and will be positioned to dynamically collaborate with industry and start-ups as part of a hospital, university and technology innovation ecosystem.”
The University of Sydney welcomed the announcement. “The government’s commitment today will fundamentally improve health outcomes for people in NSW and we are so pleased to be partnering with them and the Sydney Local Health District to bring this vision to life,” Professor Mark Scott, Vice-Chancellor and President of the University of Sydney said.
“We are proud to be key partners and are committed to utilising our renowned research expertise and experience with commercialisation to ensure the Accelerator is a success.”
Executive Dean and Pro Vice-Chancellor of the University’s Faculty of Medicine and Health Professor Robyn Ward said the Sydney Biomedical Accelerator would support multidisciplinary collaboration between world-leading teams of clinicians, scientists, engineers, computer scientists, entrepreneurs and research and industry partners.
“Once built, it will be an internationally significant clinical, teaching and research precinct, aligning with the redevelopment of Royal Prince Alfred Hospital and the NSW Government’s Tech Central project,” Professor Ward said.
“We congratulate the NSW Government on its commitment to life sciences and to future health research and commercialisation which will have far-reaching benefits.”
The primary medical research partners of the Sydney Biomedical Accelertor also welcomed the announcement, with the Chair of the Centenary Institute Board, Joseph Carrozzi AM, and its Executive Director, Professor Mathew Vadas AO, are thrilled that a biomedical complex, the Sydney Biomedical Accelerator (SBA), will now be a reality.
“Successful innovation hubs require collaboration between major anchor institutions. In the SBA, we have the Royal Prince Alfred Hospital, an iconic centre for clinical care and research which celebrates 140 years in Sydney, along with the University of Sydney, the oldest university in Australia, and the Centenary Institute, a leading medical research institute which is clinically integrated with RPA and has longstanding and strong research ties with its neighbouring universities,” added Carrozzi.
The SBA will offer a unique global concentration of biomedical research talent and research facilities and will be positioned to dynamically collaborate with industry and start-ups as part of a hospital, university and technology innovation ecosystem.
Early works for the Sydney Biomedical Accelerator will commence this year and initial occupation is expected to occur from 2026.